| Catalog No. | HV126016 |
| Brand | abinScience |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | IgG4, kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | CD85 antigen-like family member K, LIR-5, Leukocyte immunoglobulin-like receptor 5, ILT3, ILT-3, Immunoglobulin-like transcript 3, LILRB4, CD85k, Leukocyte immunoglobulin-like receptor subfamily B member 4, Monocyte inhibitory receptor HM18, LIR5 |
| References | 1. DiNardo C D, Pollyea D A, Konopleva M, et al. A first-in-human (FIH) phase 1 study of the anti-LILRB4 antibody IO-202 in relapsed/refractory (R/R) myelomonocytic and monocytic acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML)[J]. Blood, 2020, 136: 19-20. [HV126016] 2. Aribi A, Mannis G, Dunavin N, et al. Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort[J]. [HV126016] 3. van der Meer JW, et al. Abstract!. Neth J Med. 2002;60(11):418. [HV126016] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | IO-202 reverses AML cell-mediated T-cell suppression and activates T-cell cytotoxicity against leukemic cells in vitro via high-affinity binding to human LILRB4 and blockade of APOE-mediated LILRB4 activation [1]. IO-202 (15 ug/mL; 2 days) enhances DC activation (increased CD86 and HLA-DR expression) and reduces a tolerogenic phenotype (decreased CD209 expression) when used to treat healthy human donor monocyte-derived dendritic cells during LPS stimulation [3]. IO-202 (15 ug/mL; 2 days during Mo-DC culture, 4 days during T cell co-culture) enhances DC activation marker expression, IL-12 production, and T cell-derived IFNγ production when used to treat human monocyte-derived dendritic cells during CD40L-induced maturation/activation and subsequent allogeneic T cell co-culture, but has no effect on immature Mo-DCs [3]. . IO-202 (10 mg/kg; administered on day 10 and day 20 post tumor implant) combined with 10 Gy radiation therapy induces potent tumor growth inhibition and rebalances the tumor immune infiltrate toward a pro-inflammatory phenotype in a transgenic mouse Lewis lung carcinoma model [3]. . Reduced the frequencies of myeloid-derived suppressor cells (including PMN-MDSCs) among tumor-infiltrating leukocytes. Increased the frequencies of conventional CD4+ T cells and NKT cells among tumor-infiltrating leukocytes. Decreased the expression of the anti-inflammatory marker CD206 on tumor-associated macrophages (TAMs). |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | Q8NHJ6 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | IO-202, IO202, IO202 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207) Human IgG4 (S228P & L235E) Recombinant Isotype Control Antibody (HyHEL-10) (HP614107) Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107) |
Anti-Human LILRB4/CD85k/ILT3 Reference Antibody (Io-202, RUO)
Overview
Images
 Bioactivity |
Detects Human CD85k/LILRB4/ILT3 in indirect ELISAs. |
 SDS-PAGE |
SDS-PAGE for Research Grade IO-202. |